Product news

Share this article:
DDMAC sent a warning letter to Abbott requesting that the company cease dissemination of promotional Depakote and Depakote ER flashcards. According to the letter, posted to the FDA website on January 29, DDMAC found the flashcards to be misleading based on an omission of risk information and a broadened indication of Depakote ER, among other things.    
 
Indevus Pharmaceuticals received a warning letter from DDMAC on January 27 regarding a journal ad for the overactive bladder drug Sanctura. DDMAC requested that that company immediately cease dissemination of the violative ad, based on false or misleading superiority claims, omissions and minimized material risk information, and an overstated efficacy of Sanctura.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.